Abstract

**Background:** 2-Aminothiazoles are significant class of organic medicinal compounds utilized as starting material for the synthesis of diverse range of heterocyclic analogues with promising therapeutic roles as antibacterial, antifungal, anti-HIV, antioxidant, antitumor, anthelmintic, anti-inflammatory & analgesic agents.

**Experimental:** Eight compounds 1a, 2a–2g were synthesized and characterized by FTIR and NMR (1H and 13C). Evaluation of antibacterial potential against multi-drug resistant clinical isolates was performed and minimum inhibitory concentration (MIC) values were determined. Antifungal activity was also performed. Protein–ligand interactions of compounds with target enzyme were evaluated through docking studies.

**Results:** Resistance profiling of bacterical clinical isolates (MDRs) depicted that some standard drugs used were not active against these MDRs while our synthesized compounds showed good MIC values. Among all the synthesized compounds, 2a and 2b showed significant antibacterial potential towards gram-positive *Staphylococcus epidermidis* and gram-negative *Pseudomonas aeruginosa* at MIC 250 µg/mL and 375 µg/mL respectively. Likewise, compound 2d and 2g exhibited inhibitory potential against gram-positive *Staphylococcus aureus* and gram-negative *Escherichia coli* at MIC values of 250 and 375 µg/mL respectively. Compound 2b showed maximum antifungal potential against *Candida glabrata* (ATCC 62934) with a zone of inhibition 21.0 mm as compared to the reference drug nystatin which showed lesser antifungal potential with a zone of inhibition of 19.1 mm. *Candida albicans* (ATCC 60387) showed maximum sensitivity to compound 2a with a zone of inhibition 20.0 mm. Its antifungal activity is more in comparison to reference drug nystatin with exhibited the zone of inhibition of 19.3 mm. Designed compounds were docked with the target enzyme UDP-<sup>N</sup>-acetylmuramate/l-alanine ligase. The compound 2b showed highest binding affinity (−7.6 kcal/mol).

**Conclusions:** The synthesized compounds showed moderate to significant antibacterial and antifungal potential. It is clear from the binding affinities that compounds having hydroxyl group substituted on benzene ring possess strong binding affinity as compared to other analogues. These designed compounds could be considered to act as antagonists against target UDP-<sup>N</sup>-acetylmuramate/l-alanine ligase.

**Keywords:** 2-Aminothiazole, Antimicrobial evaluation, Minimum inhibitory concentration, Antifungal activity, Molecular docking, Schiff bases
Introduction
Schiff bases have gained remarkable place in medicinal chemistry because of their diverse therapeutic roles as antibacterial [1, 2], antifungal [3–6], anti-HIV [7], antioxidant, antitumor, anthelmintic [8], anti-inflammatory & analgesic agents [9]. Thiazole nucleus is present in both natural and synthetic products with notable pharmacological and therapeutic activities [10]. Thiamin also called as vitamin B1, also contains thiazole nucleus. Thiamin functions in human body as co-enzyme in metabolic pathways of carbohydrates and amino acids [11]. Synthesis of 2-amino-6-methylbenzothiazoles Schiff bases with antibacterial activity comparable to that of ampicillin, are reported [12]. 2-amino-4-substituted thiazoles are already reported for their anthelmintic, anti-leukotrienes, anticonvulsant, antimalarial and fungicidal properties [13].

The registered drugs Mirabegron (Anticholinergic agent) and Cefdinir (Antibacterial agent) belong to aminothiazole analogues [14, 15]. Since it is well known that 2-aminothiazoles are significant class of organic medicinal compounds utilized as starting material for the synthesis of diverse range of heterocyclic analogues. Therefore, the design and synthesis of ethyl-2-aminothiazole-4-carboxylate Schiff bases was targeted in this study.

Designing of evident drugs can be achieved through virtual screening and molecular docking strategies. Likewise, interpretation of probable drug specificity with target enzyme or protein can be assessed [16]. In the present study the selected uridine diphosphate-N-acetylmuramate/l-alanine ligase was selected as antimicrobial target for docking [17]. It is the bacterial enzyme that catalyzes the reaction of peptidoglycan synthesis by first amino acid addition to peptidoglycan sugar moiety. Peptidoglycan is the key element for bacterial cell wall [18]. By targeting this ligase enzyme, the bacterial cell integrity can be dismantled ultimately resulting in bacterial cell death.

Experimental
Molecular docking
Ligand designing
Eight ligands were designed using ChemSketch 12.0 (https://www.acdlabs.com/resources/freeware/). Analogues of ethyl -2-aminothiazole-4-carboxylate were designed by altering the amino group as illustrated in Fig. 1. Four aldehydes and two ketones were used to design the compounds form 2a–2h. Molecular properties were determined using ChemSketch Tool (https://www.acdlabs.com/resources/freeware/). Chemo-informatics, ADME properties and drug likeliness were determined by following Lipinski rule while associated parameters of designed ligands were predicted by Molinspiration (https://www.molinspiration.com/) and pkCSM online tool [19, 20]. The toxicity profile was obtained using TOXTREE and pkCSM online tool [21].

Pocket identification and docking of designed compounds
Pocket identification was accomplished via Dogsitescorer [22]. Crystal structure of bacterial target enzyme UDP-N-acetyluramyluramyl/l-alanine ligase was taken from databank (https://www.rcsb.org/) (PDB ID: 1GQQ). Enzyme-Ligand docking was accomplished with PyRx [23], via AutoDock VINA module [24]. Docking coordinates of x = 42.396, y = 47.393 and z = 84.654 with dimensions x = 47.187, y = 23.629 and z = 38.776 were used according to the best binding site predicted by Dogsitescorer. Open Babel GUI and Discovery Studio 2017 R2 Client (https://www.3dsbiovia.com/) were utilized for preliminary procedures and elaboration of enzyme ligand interactions respectively [25].

Chemistry
Ethyl bromopyruvate (technical grade, 90%), thio-urea (ACS reagent) benzaldehyde (ReagentPlus® 99%), salicylaldehyde (reagent grade, 98%), 3-hydroxybenzaldehyde (AR ≥ 99%), 4-hydroxybenzaldehyde (Analytical standard), 4-hydroxy-3-methoxybenzaldehyde (ReagentPlus® 99%), acetophenone (Analytical
standard), 2′-hydroxyacetophenone (ReagentPlus® 99%). Ethanol (absolute, ACS reagent) and glacial acetic acid (100%, anhydrous for analysis ACS, ISO reagent) were used purchased from Sigma Aldrich and Merck. Synthesized compounds were purified by recrystallization in appropriate solvents and examined through thin layer chromatography (Merck Silica gel 60 F 254). Melting points were determined by using digital Gallenkamp model MPD BM 3.5 apparatus. Characterization of synthesized compounds was made through spectrophotometric analysis; FT-IR (Thermoscientific NICOLET IS10 spectrophotometer), 1H & 13C NMR (Bruker AM-300 and AM-100 spectrophotometer) using DMSO and CDCl 3 respectively. Elemental analysis values were recorded on Model ANALYST 2000 CHNS, Perkin Elmer Analyzer. Multiskan™ GO Microplate Spectrophotometer was used to quantify synthesized compounds for accuracy, precision and sensitivity [26].

General procedure for the preparation of ethyl 2-aminothiazole-4-carboxylate (1a)
Ethyl bromopyruvate (2 mol) and of thiourea (3 mol) in 100 mL of ethanol (99.9%) was refluxed for 24 h. Progress of the reaction was monitored by TLC (petroleum ether: ethyl acetate, 1:3). After completion, the reaction mixture was cooled to room temperature, concentrated and poured into ice cold water and basified (pH 10) resulting in separation of off-white precipitation that was recrystallized using ethanol.

Yield 70%, m.p. 175–177 °C, R f 0.71 (petroleum ether: ethyl acetate, 1:3); IR (KBr) cm⁻¹: 1690 (C=O ester), 3000 (C–H), 3300–3150 (N–H amine), 1566 (C=C); 1H-NMR (Cholroform, δ ppm): δ = 4.34 (q, 2H, CH2), 1.38 (t, 3H, CH3), 7.41 (s, 1H, Thiazole), 5.85 (s, 2H, NH2); Elemental analysis: C6H8N2O2S, Calculated: C 41.81%, H 4.65%, N 16.26% O 18.59% S 18.59%; Found C 41.79%, H 4.64%, N 16.26% O 18.58% S 18.57%.

Table 1 Physical data of synthesized compounds (1a, 2a–2g)

| Comp | Molecular formula | MW calculated (g/mol) | M.P (°C) | Physical state | Color | % Yield | Rf Value |
|------|------------------|-----------------------|----------|----------------|-------|---------|----------|
| 1a   | C6H8N2O2S        | 172.20                | 175–177  | Solid          | Off white-pale yellow | 70      | 0.71     |
| 2a   | C13H12N2O2S      | 260.31                | 160–162  | Crystal        | Light brown            | 50      | 0.61     |
| 2b   | C13H12N2O2S      | 276.31                | 198–199  | Solid          | Light brown            | 56      | 0.64     |
| 2c   | C13H12N2O2S      | 276.31                | 195–197  | Solid          | Orange                  | 54      | 0.66     |
| 2d   | C13H12N2O2S      | 276.31                | 200–202  | Solid          | Brown                   | 60      | 0.69     |
| 2e   | C13H12N2O2S      | 306.33                | 196–198  | Solid          | Light brown             | 50      | 0.61     |
| 2f   | C13H12N2O2S      | 274.33                | 190–192  | Crystal        | Light brown             | 52      | 0.59     |
| 2g   | C13H12N2O2S      | 290.33                | 164–165  | Crystal        | Light brown             | 62      | 0.60     |

Solvent system: ethyl acetate: petroleum ether (3:1), TLC silica HF-254.
Ethyl 2-[[((E)-(3-hydroxyphenyl)methylidene]amino]-1,3-thiazole-4-carboxylate (2c) Yield 54%, m.p. 195–197 °C, Rf 0.66 (petroleum ether: ethyl acetate, 1:3); IR (KBr) cm⁻¹: 1690 (C=O ester), 1502 (C=C), 1614 (C=N), 3259 (OH); ¹H NMR (DMSO, δ ppm): δ = 4.21 (q, 2H, CH₂), 1.24 (t, 3H, CH₃), 7.43 (s, 1H, Thiazole), 7.30 (m, 4H, Ar), 8.89 (s, 1H, H–C=N); ¹H NMR (DMSO, δ ppm): δ = 4.25 (q, 2H, CH₂), 1.25 (t, 3H, CH₃), 7.42 (s, 1H, Thiazole), 7.20 (m, 4H, Ar), 9.48 (s, 1H, H–C=N); ¹H NMR (DMSO, δ ppm): δ = 4.21 (q, 2H, CH₂), 1.23 (t, 3H, CH₃), 7.43 (s, 1H, Thiazole), 7.25 (m, 4H, Ar), 3.34 (s, 3H, CH₃–C=N); ¹H NMR (DMSO, δ ppm): δ = 4.21 (q, 2H, CH₂), 1.26 (t, 3H, CH₃), 7.45 (s, 1H, Thiazole), 7.25 (m, 4H, Ar), 3.38 (s, 3H, CH₃–C=N); elemental analysis: C₁₃H₁₂N₂O₃S, calculated: C 56.458%, H 4.343%, N 11.58%; found C 56.45%, H 4.34%, N 11.57%.

Ethyl 2-[[((E)-(4-hydroxy-3-methoxyphenyl)methylidene]amino]-1,3-thiazole-4-carboxylate (2d) Yield 60%, m.p. 200–202 °C, Rf 0.59 (petroleum ether: ethyl acetate, 1:3); IR (KBr) cm⁻¹: 1688 (C=O ester), 1517 (C=C), 1612 (C=N), 3250 (OH); ¹H NMR (DMSO, δ ppm): δ = 4.25 (q, 2H, CH₂), 1.25 (t, 3H, CH₃), 7.42 (s, 1H, Thiazole), 7.20 (m, 4H, Ar), 9.48 (s, 1H, H–C=N); ¹H NMR (DMSO, δ ppm): δ = 4.25 (q, 2H, CH₂), 1.25 (t, 3H, CH₃), 7.42 (s, 1H, Thiazole), 7.20 (m, 4H, Ar), 9.48 (s, 1H, H–C=N); ¹H NMR (DMSO, δ ppm): δ = 4.25 (q, 2H, CH₂), 1.25 (t, 3H, CH₃), 7.42 (s, 1H, Thiazole), 7.20 (m, 4H, Ar), 9.48 (s, 1H, H–C=N); elemental analysis: C₁₄H₁₄N₂O₄S, calculated: C 61.24%, H 5.103%, N 9.14%; found C 61.24%, H 5.10%, N 9.64%.

Antimicrobial assay

Resistance profiling

Analysis of resistance pattern of pathogenic microbe (resistant, intermediate, susceptible), antibiotic sensitivity assay was performed. Fresh cultures of bacterial strains were made on nutrient agar and incubated for 24 h at 37 °C. The following day isolated colonies from bacterial cultures were picked and dissolved in 1 mL of PBS (autoclaved normal saline) and inoculum turbidity was then confirmed with 0.5% McFarland standard [29].

Dried Muller Hinton (MH) agar plates were used for resistance profiling. With the help of sterilized syringe antibiotic discs of known concentration were placed on MH agar plates namely Cefepime, Ciprofloxacin, Imipenem, Cefoxitin, Amoxicillin, Aztreonam, Tetracycline, Cefazidime, Minocyclin, Gentamycin, Co-trimoxazole, Colistin, Clindamycin, Vancomycin, Doxycycline, Erythromycin and Chloramphenicol. Later these plates were incubated for 24 h at 37 °C. Afterwards, resistance pattern of particular strain was studied based upon the zone of inhibition measurement following the CLSI 2017 guideline [30, 31].

Quantification by nanophotometer

For quantification purpose Multiskan™ GO Microplate Spectrophotometer was used. The standard stock solution of 2 mg/mL was prepared for each active compound by adding 0.02 g in 10 mL distilled water. From this stock solution various working dilutions ranging from 40 to 2000 μg/mL were prepared in triplicate. Wave scan of the dilutions was performed between 200–900 nm and λmax value was obtained from absorbance spectra. Afterwards,
particular active compound $\lambda_{\text{max}}$ was used to measure optical density of dilutions and standard curve was plotted.

**Antibacterial activity and minimum inhibitory concentration**
Antimicrobial activity was assessed by broth dilution method. Clinical isolates were obtained from Microbiology and Public Health Laboratory culture collection, COMSATS University, Islamabad. *Staphylococcus epidermidis* (MDR) and *Staphylococcus aureus* (MDR) were the gram-positive and *Escherichia coli* (MDR) and *Pseudomonas aeruginosa* (MDR) were the gram-negative strains selected for this study.

Broth dilution method was performed for antibacterial activity of synthesized compounds against selected clinical microbes. MIC was calculated by broth dilution method, stock solution of 2 mg/mL for each active compound with DMSO 20% as solvent was prepared which was further consumed for preparing working dilutions ranging from 40 to 1000 μg/mL. The selected model bacterial strains were subjected to these active compounds dilutions separately and OD values were obtained at 595 nm [32].

**Antifungal assay**
Agar well diffusion method was utilized for antifungal assay using nystatin as positive control while DMSO (20%) was employed as a negative control. Sabouraud dextrose agar (SDA) and nutrient broth were prepared and sterilized by autoclaving at 121 °C for 15 min. Sterile agar plates were prepared by pouring the sterile agar in disposable sterile plates and incubated for 24 h for sterility check at 28 °C after congealing. The fungal strains *Candida albicans* (ATCC 60387) and *Candida glabrata* (ATCC 62934) were refreshed by inoculation in nutrient broth followed by 24 h incubation at 28 °C. Lawn of both fungal strains were made on nutrient agar plates and wells were made by employing sterile borer (6 mm). 50 μL of the synthesized compounds, nystatin and DMSO (20%) were poured through micropipette into individual well. The concentration of synthesized compounds, positives and negative controls used were 10 mg/mL and 750 μg/mL respectively. Plates were sealed by using paraffin film (Parafilm M) and incubated for 3–7 days at 28 °C to be examined for zone of inhibition that reflects the antifungal potential [33].

**Result and discussion**
**Chemistry**
Ethyl 2-aminothiazole-4-carboxylate was synthesized by reacting ethyl bromopyruvate and thiourea. Ethyl 2-aminothiazole-4-carboxylate (1a) was collected as off-white precipitates. Schiff bases 2a–2g were synthesized by reacting Ethyl 2-aminothiazole-4-carboxylate (1a) with different aldehydes and ketones as shown in Fig. 1.

Purity of all the synthesized compounds was ensured by recrystallization in appropriate solvents and checked by thin layer chromatography plates using ethyl acetate: petroleum ether (3:1) solvent system. Single spot yielded by each synthesized compound was obtained.

Synthesis of compound 1a was confirmed through FTIR and $^1$H NMR spectral data. Strong peak of C=O (ester) in case of each compound from 2a to 2e at cm$^{-1}$: 1690, 1687, 1690, 1688 and 1696 respectively. Absence of amine peak and appearance of C=N (imine) confirmed the synthesis of Schiff bases in case of each derivative. FTIR spectral data showed strong peak of C=N (imine) in case of each compound from 2a to 2e at cm$^{-1}$: 1616, 1617, 1614, 1612 and 1619 respectively. C–H stretch was observed at cm$^{-1}$: 3023, 2975, 2983, 2953 and 3030 for compounds 2a–2e respectively. $^1$H NMR spectral data showed singlet of imine in case of each synthesized compound from 2a to 2e; ppm: 9.47, 9.76, 8.89, 9.48 and 8.42 respectively. Moreover, quartet of CH$_2$ of synthesized compounds from 2a to 2e was observed a ppm: 4.25, 4.20, 4.21, 4.25 and 4.20 respectively. While in compound 2g peak of C=O (ester) was observed at 7.45 ppm were observed. Moreover, quartet and triplet of CH$_3$ and CH$_3$ was observed 4.34 ppm and 1.38 ppm respectively.

Confirmation of synthesized compounds was done by FTIR and $^1$H NMR spectral data. FTIR spectral data showed strong peak of C=O (ester) in case of each compound 1a at cm$^{-1}$: 1687, 1687, 1688, 1690 and 1696 respectively. Absence of amine peak and appearance of C=N (imine) confirmed the synthesis of Schiff bases in case of each derivative. FTIR spectral data showed strong peak of C=N (imine) in case of each compound from 2a to 2e at cm$^{-1}$: 1616, 1617, 1614, 1612 and 1619 respectively. C–H stretch was observed at cm$^{-1}$: 3023, 2975, 2983, 2953 and 3030 for compounds 2a–2e respectively.

**Antibacterial assay of synthesized compounds**
All experiments were conducted in the boundaries of ethical principles and there was no involvement of human or animal samples in this project.
Selected clinical gram-negative and gram-positive bacteria were subjected to antibiotic disks diffusion by Kirby Bauer assay and their pattern of resistance were determined. The resistance pattern of synthesized derivatives is given in Table 2.

Quantification
Spectrophotometric analysis was utilized for the quantification of compounds 2a, 2b, 2d and 2g. After performing wave scan the values obtained for \( \lambda_{\text{max}} \) were 2a at 320 nm, 2b at 420 nm, 2d at 310 nm and 2g at 325 nm. \( \lambda_{\text{max}} \) values were used to measure dilutions optical density (OD). These OD values were used to plot the standard curve and coefficient of determination (\( R^2 \)) value was calculated. The curve was plotted between OD values on y-axis while the concentration values on horizontal x-axis. From regression analysis, the \( R^2 \) values obtained for compound 2a, 2b, 2d and 2g were 0.976, 0.999, 0.951 and 0.997 respectively. Values closer to 1 indicated the fitness of the data against the regression line. The graphs plotted are given in Fig. 2.

Minimum inhibitory concentration (MIC)
All the synthesized compounds manifested mild to moderate antibacterial potential. The lowest concentration of the drug exhibiting bacteriostatic action is stated to be the Minimum inhibitory concentration (MIC) of the drug. The MIC of synthesized derivatives is given in Table 3. Compound 2a and 2b showed quite good MIC of 250 µg/mL against gram-positive Staphylococcus epidermidis (MDR). Likewise compound 2d and 2g exhibited MIC of 250 µg/mL against gram-positive bacteria S. aureus (MDR). Compounds 2d and 2g exhibited MIC of 375 µg/mL against E. coli (gram-negative) (MDR). While compounds 2a and 2b showed MIC of 375 µg/mL against P. aeruginosa (gram-negative) (MDR).

Antifungal activity
Compounds 2a, 2b and 2d showed maximam antifungal potential against Candida glabrata (ATCC 62934) with a zone of inhibition (mm) of 13.0, 21.0 and 13.1 respectively. Candida albicans (ATCC 60387) showed sensitivity to compounds 2a, 2b 2d, 2f and 2g with a zone of inhibition (mm) of 20.0, 13.8, 19.1, 15.4 and 14.9 respectively (Table 4).

Insilico studies
Best compounds are selected computationally by analyzing them for their chemo-informatics and ADMET properties as given in Tables 5 and 6. According to literature, established qualifying range for log P value is \((-0.4 \text{ to } 5.6)\). All compounds log p value lie within the limits. Molar refractivity should lie between (40 to 130) while molecular weight limits are (160 to 480). Moreover,
the required number of atoms of compounds should lie between (20 to 70). Number of rotatable bonds should be less than 10. All compounds have 4 rotatable bonds except the compounds 2e and 2h that are having 5 rotatable bonds. All the compounds are fulfilling the set criteria for above parameters. Moreover, the drug likeliness following the Lipinski rule is also fulfilled. That’s why these compounds can be used as drug candidates.

Toxicity profile was determined by using TOXTREE and pkCSM online tools. All the compounds employed were having a therapeutically safe profile excluding compound 2h, which holds genotoxic potential. Therefore, compound 2h was not utilized in the docking step. Table 7 contains the toxicity profile of designed compounds.

Our designed compounds were docked with the target enzyme UDP-N-acetylmuramate/l-alanine ligase and binding affinities were determined. The binding pocket of target enzyme was identified through Dogsitescorer. All the compounds docked with the biggest pocket of the enzyme target located on chain B. The volume and surface of the pocket is 963.07 [Å³] and 1100.44 [Å²]
respectively. While the pocket possesses quite good drug score of 0.77. Figure 3 illustrates the druggable pocket of UDP-\(\text{N}\)-acetylmuramate/l-alanine ligase target enzyme.

Results of docking of compounds are displayed (Table 8) in terms of free binding energy of ligand also stated as binding affinity (kcal/mol), root mean square deviation (RMSD) upper bound along with values of RMSD lower bound of all the docked ligands as well. Strength of binding interactions between ligand and receptor is termed as affinity. Calculation of RMSD values is based on the best binding pose and it employs movable heavy atoms only. Among the compounds 2a, 2b, 2d and 2g; 2b shown the strongest binding affinity of −7.6 kcal/mol against UDP-\(\text{N}\)-acetylmuramate/l-alanine ligase. While compounds 2a, 2d and 2g exhibited binding affinity of −6.8, −7.3, −7.1 and −6.9 kcal/mol respectively. It is inferred from the binding affinities that the compounds having hydroxyl group substituted on benzene ring possess strong binding affinity as compared to others. These designed compounds could be considered as antagonist lead molecules for target UDP-\(\text{N}\)-acetylmuramate/l-alanine ligase. The enzyme-ligand binding interactions of compounds 2b, 2c, 2d, and 2g with target UDP-\(\text{N}\)-acetylmuramate/l-alanine ligase are shown in Figs. 4, 5, 6, 7 respectively.

### Conclusion

The aim of the study is to design and synthesize novel Schiff base derivatives of ethyl-2-aminothiazole-4-carboxylate. Characterization was done by FTIR, \(^1\)H NMR and \(^{13}\)C NMR spectral data and quantification is done through Multiskan™ GO Microplate Spectrophotometer. Synthesized derivatives are screened for their antibacterial potential against Multi drug resistant (MDR) clinical isolates. Moreover, synthesized derivatives also exhibited good antifungal activity against ATCC fungal strains. It is anticipated that these synthesized compounds are promising potent antibacterial therapeutic agents. In future it is aimed to develop a pharmacophore model from these

### Table 4 Antifungal activity of synthesized compounds (1a, 2a–2g)

| Compounds | Candida glabrata (zone of inhibition mm) | Candida albicans (zone of inhibition mm) |
|-----------|----------------------------------------|----------------------------------------|
| 1a        | 11.0                                   | 11.1                                   |
| 2a        | 13.0                                   | 20.0                                   |
| 2b        | 21.0                                   | 13.8                                   |
| 2c        | 10.9                                   | 11.0                                   |
| 2d        | 13.1                                   | 11.8                                   |
| 2e        | 11.5                                   | 19.1                                   |
| 2f        | 10.8                                   | 15.4                                   |
| 2g        | 12.0                                   | 14.9                                   |
| Nystatin  | 19.1                                   | 19.3                                   |

Concentration of each compound (0.5 mg/50 μL)

### Table 5 Chemo-informatics of compounds 2a–2h

| Chemo-informatics | 2a | 2b | 2c | 2d | 2e | 2f | 2g | 2h |
|-------------------|----|----|----|----|----|----|----|----|
| Mol. formula      | \(\text{C}_{13}\text{H}_{12}\text{N}_{2}\text{O}_{2}\text{S}\) | \(\text{C}_{13}\text{H}_{12}\text{N}_{2}\text{O}_{3}\text{S}\) | \(\text{C}_{13}\text{H}_{12}\text{N}_{2}\text{O}_{3}\text{S}\) | \(\text{C}_{13}\text{H}_{12}\text{N}_{2}\text{O}_{3}\text{S}\) | \(\text{C}_{14}\text{H}_{14}\text{N}_{2}\text{O}_{4}\text{S}\) | \(\text{C}_{14}\text{H}_{14}\text{N}_{2}\text{O}_{2}\text{S}\) | \(\text{C}_{14}\text{H}_{14}\text{N}_{2}\text{O}_{3}\text{S}\) | \(\text{C}_{15}\text{H}_{17}\text{N}_{3}\text{O}_{2}\text{S}\) |
| Molecular weight (g/mol) | 260.31 | 276.31 | 276.31 | 276.31 | 306.33 | 274.33 | 290.33 | 303.38 |
| No. of HBA        | 5  | 6  | 6  | 6  | 7  | 5  | 6  | 6  |
| No. of HBD        | 0  | 1  | 1  | 1  | 1  | 0  | 1  | 0  |
| No. of rotatable bonds | 4  | 4  | 4  | 4  | 5  | 4  | 4  | 5  |
| Mol. Log\(\text{P}\)   | 3.36 | 2.98 | 3.10 | 3.10 | 3.07 | 3.33 | 2.95 | 3.48 |
| Mol. PSA (\(\text{Å}^2\)) | 39.17 | 55.71 | 56.78 | 56.78 | 63.34 | 38.50 | 55.04 | 41.97 |
| Molar refractivity (\(\text{cm}^2\)) | 73.33 | 74.18 | 74.18 | 74.18 | 79.99 | 77.75 | 78.60 | 86.13 |
| Density (g/cm\(^3\)) | 1.22 | 1.32 | 1.32 | 1.32 | 1.32 | 1.20 | 1.29 | 1.19 |
| Surface tension (dyne/cm) | 46.5 | 51.0 | 51.0 | 51.0 | 48.5 | 43.8 | 47.8 | 43.4 |
| Polarizability (\(\text{Å}^3\)) | 29.07 | 29.40 | 29.40 | 29.40 | 31.71 | 30.82 | 31.16 | 34.14 |
| Molar volume (\(\text{Å}^3\)) | 238.45 | 248.98 | 249.07 | 249.00 | 281.72 | 263.23 | 274.41 | 288.00 |
| Drug likeness     | −0.32 | −0.19 | 0.30 | 0.22 | 0.20 | −0.46 | 0.15 | −0.48 |
| Lipinski’s rule validation | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |

HBA hydrogen bond donor, HBD hydrogen bond acceptor, PSA polar surface area
### Table 6  ADME assessment of compounds 2a–2h

| ADME properties       | 2a       | 2b       | 2c       | 2d       | 2e       | 2f       | 2g       | 2h       |
|-----------------------|----------|----------|----------|----------|----------|----------|----------|----------|
| WS (log mol/L)        | −3.147   | −3.599   | −3.644   | −3.8     | −3.901   | −3.538   | −3.742   | −4.122   |
| IS (% abs)            | 95.067   | 92.136   | 93.112   | 92.486   | 94.048   | 94.329   | 91.609   | 95.929   |
| SP (logKp)            | −2.46    | −2.865   | −2.826   | −2.837   | −2.943   | −2.508   | −2.908   | −2.61    |
| BBBP (logBB)          | 0.055    | −0.545   | −0.549   | −0.574   | −0.726   | 0.389    | −0.518   | 0.291    |
| CNSP (logPS)          | −2.215   | −2.407   | −2.905   | −2.915   | −2.973   | −2.768   | −2.864   | −2.772   |
| Metabolism            | CYP3A4 inhibitor | Yes | No | No | No | No | No | No |
| Excretion             | TC (log mL/min/kg) | 0.297 | 0.248 | 0.192 | 0.07 | 0.273 | 0.254 | 0.278 | 0.278 |

**WS** water solubility, **IS** intestinal solubility (% abs absorption), **SP** skin permeability, **BBBP** blood brain barrier permeability, **CNSP** Central Nervous System permeability, **TC** total clearance

### Table 7  Toxicity Profile of compounds 2a–2h

| Toxicity                                      | 2a       | 2b       | 2c       | 2d       | 2e       | 2f       | 2g       | 2h       |
|-----------------------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|
| Nongenotoxic carcinogenicity                  | No       | No       | No       | No       | No       | No       | No       | No       |
| Genotoxic carcinogenicity                     | No       | No       | No       | No       | No       | No       | No       | Yes      |
| Invitro mutagenicity alerts (Ames test)       | No       | No       | No       | No       | No       | No       | No       | No       |
| Potential for *S. typhimurium*                | No       | No       | No       | No       | No       | No       | No       | No       |
| Max. tolerated dose log (mg/kg/day)           | 0.295    | 0.387    | 0.684    | 0.711    | 1.099    | 0.758    | 0.393    | 0.306    |
| ORAT (LD50) (mol/kg)                          | 2.343    | 2.285    | 2.427    | 2.343    | 2.599    | 2.519    | 2.366    | 2.571    |
| HT                                            | Yes      | No       | No       | No       | No       | Yes      | No       | Yes      |
| SS                                            | No       | No       | No       | No       | No       | No       | No       | No       |

**HT** hepatotoxicity, **SS** skin sensitization, **ORAT** oral rat acute toxicity

---

**Fig. 3** a depicts the ligand binding pocket of UDP-N-acetylmuramate/l-alanine ligase target protein while b is showing the enlarged view of chain B ligand binding pocket.
Table 8 Docking Scores of first three best docked posses of Compound 2a, 2b, 2d and 2g with UDP-\textit{N}-acetylmuramate/\textit{l}-alanine ligase

| Target protein | Compound | Ligand modes | Binding affinity | rmsd/ub | rmsd/lb |
|----------------|----------|--------------|------------------|---------|---------|
| UDP-\textit{N}-acetylmuramate/\textit{l}-alanine ligase | 2a | 0 | $-6.8$ | 0 | 0 |
| | 2a | 1 | $-6.7$ | 28.075 | 26.052 |
| | 2a | 2 | $-6.6$ | 28.511 | 26.881 |
| | 2b | 0 | $-7.6$ | 0 | 0 |
| | 2b | 1 | $-7.0$ | 28.764 | 27.311 |
| | 2b | 2 | $-7.0$ | 28.373 | 27.402 |
| | 2d | 0 | $-7.3$ | 0 | 0 |
| | 2d | 1 | $-7.0$ | 28.595 | 27.20 |
| | 2d | 2 | $-7.0$ | 28.136 | 26.504 |
| | 2g | 0 | $-7.1$ | 0 | 0 |
| | 2g | 1 | $-6.9$ | 7.342 | 2.41 |
| | 2g | 2 | $-6.8$ | 3.16 | 2.568 |

*UDP uridine diphosphate*

**Fig. 4** Interaction of UDP-\textit{N}-acetylmuramate/\textit{l}-alanine ligase with compound 2a. **a** Two dimensional diagram of protein–ligand interaction of UDP-\textit{N}-acetylmuramate/\textit{l}-alanine ligase with compound 2a. **b** Three dimensional view of compound 2a docking with UDP-\textit{N}-acetylmuramate/\textit{l}-alanine ligase, illustrates the pocket amino acids and bond distances of interacting groups of protein receptor and the ligand.
Fig. 5 Interaction of UDP-\(N\)-acetylmuramate/\(l\)-alanine ligase with compound 2b. 

a Two dimensional diagram of protein–ligand interaction of UDP-\(N\)-acetylmuramate/\(l\)-alanine ligase with compound 2b. 

b Three dimensional view of compound 2b docking with UDP-\(N\)-acetylmuramate/\(l\)-alanine ligase, illustrates the pocket amino acids and bond distances of interacting groups of protein receptor and the ligand.

Fig. 6 Interaction of UDP-\(N\)-acetylmuramate/\(l\)-alanine ligase with compound 2d. 

a Two dimensional diagram of protein–ligand interaction of UDP-\(N\)-acetylmuramate/\(l\)-alanine ligase with compound 2d. 

b Three dimensional view of compound 2d docking with UDP-\(N\)-acetylmuramate/\(l\)-alanine ligase, illustrates the pocket amino acids and bond distances of interacting groups of protein receptor and the ligand.
compounds to have a best lead molecule for the UDP-\(N\)-acetylmuramate/l-alanine ligase target enzyme.

Abbreviations

ATCC: American Type Culture Collection; CDCl3: deuterated chloroform; DMSO: dimethyl sulfoxide; FTIR: Fourier transform infrared; MIC: minimum inhibitory concentration; NMR: nuclear magnetic resonance; SDA: sabouraud dextrose agar; TLC: thin layer chromatography.

Acknowledgements

We are thankful to Dr. Muhammad Imran Assistant Professor, Department of Biosciences, Comsats University Islamabad for his valuable support and suggestions.

Authors’ contributions

Authors HN and RZP carried out study design, supervised the work and refined the manuscript for publication. SE1 did experimental work in synthesis of compounds, molecular docking and antifungal assay and prepared the manuscript. SE2 and SS performed anti-microbial evaluation including resistant profiling, quantification and minimum inhibitory concentration assays and prepared the related manuscript. All authors read and approved the final manuscript.

Funding

Not applicable. (No specific funding or grant).

Availability of data and materials

All the relevant data supporting the conclusions of this article is included in the article.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Pharmaceutical Chemistry, Riphah Institute of Pharmacetical Sciences, Riphah International University, Islamabad, Pakistan.
2 Research Center for Modeling and Simulation, National University of Science and Technology, Islamabad, Pakistan.
3 Department of Pharmacognosy, Riphah Institute of Pharmacetical Sciences, Riphah International University, Islamabad, Pakistan.
4 Microbiology and Public Health Laboratory, Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.

References

1. Ajani OO, Obafemi CA, Nwinyi OC, Akinpelu DA (2010) Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives. Bioorg Med Chem 18(1):214–221
2. Ashraf MA, Mahmood K, Wajid A, Maah MJ, Yusoff I (2011) Synthesis, characterization and biological activity of Schiff bases. IPCBEE. 10:1–7
3. Karegoudar P, Karthikeyan MS, Prasad DJ, Mahalinga M, Holla BS, Kumari NS (2008) Synthesis of some novel 2, 4-disubstituted thiazoles as possible antimicrobial agents. Eur J Med Chem 43(2):261–267
4. Turan-Zitouni G, Kaplancıklı ZA, Yıldız MT, Chevallet P, Kaya D (2005) Synthesis and antimicrobial activity of 4-phenyl/cyclohexyl-5-(1-phenoxyethyl)-3-(N-(2-thiazolyl) acetamido) thio-4H-1, 2, 4-triazole derivatives. Eur J Med Chem 40(6):607–613
5. Rezanka T, Sobotka M, Spízek J, Sigler K (2006) Pharmacologically active sulfur-containing compounds. Anti Infect Agents Med Chem Form Curr Med Chem Anti Infect Agents 5(2):187–224
6. Costa M, Costa-Rodrigues J, Fernandes MH, Barros P, Vasconcelos V, Martins R (2012) Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis. Marine Drugs 10(10):2181–2207
7. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, Teitelbaum SL, Ross FP (2004) The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 114(2):206–213
8. Morgan JB, Mahdi F, Liu Y, Cothankedaswamy V, Jekabsons MB, Johnson TA, Sashidhara KV, Crews P, Nagle DG, Zhou YD (2010) The marine sponge metabolite mycothiazole: a novel prototype mitochondrial complex I inhibitor. Bioorg Med Chem 18(16):5988–5994
9. Siddiqui N, Arya SK, Ahsan W, Azad B. Int J Drug Dev Res | October–December 2011 | vol. 3 | Issue 4 | ISSN 0975-9344 | http://www ijddr in Covered in Official Product of Elsevier, The Netherlands® 2010 IJDOR. Int. J. Drug Dev Res. 2011;3(4):156–64
10. de Souza MV (2005) Synthesis and biological activity of natural thiazoles: an important class of heterocyclic compounds. J Sulfur Chem 26(4–5):429–449

Fig. 7 Interaction of UDP-\(N\)-acetylmuramate/l-alanine ligase with compound 2g. a Two dimensional diagram of protein–ligand interaction of UDP-\(N\)-acetylmuramate/l-alanine ligase with compound 2g. b Three dimensional view of compound 2g docking with UDP-\(N\)-acetylmuramate/l-alanine ligase, illustrates the pocket amino acids and bond distances of interacting groups of protein receptor and the ligand.
11. Siddiqui N, Arshad MF, Ahsan W, Alam MS (2009) Thiazoles: a valuable insight into the recent advances and biological activities. Int J Pharm Sci Drug Res. 1(3):136–143
12. Kajal A, Bala S, Kamboj S, Sharma N, Saini V (2013) Schiff bases: a versatile pharmacophore. J Catal 27:2013
13. Khalifa ME (2018) Recent developments and biological activities of 2-aminothiazole derivatives. Acta Chim Slov 65(1):1–22
14. Sacco E, Bientinesi R (2013) Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: an up-to-dated review. World J Obstet Gynecol 2(4):65–73
15. Guay DR (2002) Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 24(4):473–489
16. Strogonov OV, Novikov FN, Stroykov VS, Kulkov V, Chilov GG (2008) Lead finder: an approach to improve accuracy of protein–ligand docking, binding energy estimation, and virtual screening. J Chem Inf Model 48(12):2371–2385
17. Jin H, Emanuele JJ, Fairman R, Robertson JG, Hail ME, Ho HT, Falk PJ, Vilafraanca JJ (1996) Structural studies of Escherichia coli UDP-N-acetylmuramoyl-l-alanine ligase. Biochemistry 35(5):1423–1431
18. Alderwick LJ, Harrison J, Lloyd GS, Birch HL (2015) The Mycobacterial cell wall—peptidoglycan and arabinogalactan. Cold Spring Harb Perspect Med 5(8):a021113
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2012) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1(64):4–17
20. Pires DE, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072
21. Patlewicz G, Jeliazkova N, Safford RJ, Worth AP, Aleksiev B (2008) An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. SAR QSAR Environ Res 19(5–6):495–524
22. Fährrolfes R, Bietz S, Flachsenberg F, Meyder A, Nittinger E, Otto T, Volkamer A, Rarey M (2017) Development of cefotaxime impregnated chitosan as nano-antibiotics: De novo strategy to combat biofilm forming multi-drug resistant pathogens. Front Microbiol 18(7):330
23. Sen A, Batra A (2012) Evaluation of antimicrobial activity of different solvent extracts of medicinal plant: melia azedarach L. Int J Curr Pharm Res. 4(2):67–73

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.